


Flexipharm Austrading Announces Protective Vial Sleeve to Enhance User Safety and Performance of Lead Product, Arsenic Trioxide Phebra

FARNBOROUGH, England, September 11th 2020: Flexipharm Austrading, the UK specialty pharmaceutical company focused on supplying the NHS with *Better, Critical Care Medicines*, today announced that its lead product, Arsenic Trioxide Phebra 1mg/ml concentrate solution for infusion, indicated for the treatment of acute promyelocytic leukaemia¹, will now be supplied with the **additional safety feature of a clear plastic sleeve and a rigid plastic base cup to individual vials.**



The sleeve, also termed “wrap”, is made from ultra-thin heat-shrinkable polyethylene terephthalate (or PET) extruded material. The sleeve (or wrap) is impact resistant and highly transparent, allowing clarity for easy content inspection, while the base cup ensures that the vial is always stable when placed on surfaces¹.

Arsenic Trioxide Phebra is already supplied in a high quality, Type 1 moulded glass vial. This addition **further enhances breakage resistance**. Also, the protective vial sleeve (or wrap) has been designed to trap possible drug substance within the sleeve if the vial is compromised through a breakage or surface damage, **reducing possible contamination** of production equipment and **minimising the possibility of product contact for the end user**. Sleeves are heat shrunk around the contours of the vial and aluminium crimp seal ensuring a tight fit, essential for both efficacy and aesthetics.

Arsenic Trioxide Phebra is the first and currently the only arsenic trioxide product to have this enhanced user safety feature. The use of high quality, Type 1 moulded glass vials, best-in-class stability data and this enhancement for safety of users of the product, makes Arsenic Trioxide Phebra a high quality and very user-friendly arsenic trioxide product for NHS staff preparing infusions of this important medicine.

The updated Arsenic Trioxide Phebra product including vials with the sleeve and base cup, will be supplied from 14th September

Notes to editors

About Flexipharm Austrading

Flexipharm Austrading's vision is to become a UK-based specialty pharmaceutical company that is genuinely respected and trusted by NHS hospitals. It was set up in 2018 by Michael Clark, an experienced specialty pharmaceutical company founder and board director.

Flexipharm Austrading has a singular focus on established molecules embedded in hospital use where there are concerns around security of ongoing supply; where the current presentation is not optimal

for the needs of the NHS staff; and where the current presentations can contribute to medication errors.

Flexipharm Austrading has a deep understanding of the conditions where its medicines are used and builds enduring meaningful dialogue with the NHS staff involved in using these medicines. It has an exclusive distribution agreement with Phebra Pty Ltd, an Australian pharmaceutical company that develops and manufactures injectable pharmaceutical products. Flexipharm Austrading will be launching additional products from the Phebra portfolio in the UK in the next 12 months.

For further information visit our website, www.flexipharmaustrading.com.

For more information please contact:

Flexipharm Austrading

Michael Clark
Tel: +44 (0) 1628 290 433
inquiries@flexipharmaustrading.com

Optimum Strategic Communications

Mary Clark, Charlotte Hepburne-Scott
Tel: +44 (0) 203 922 0891
healthcare@optimumcomms.com

References

1. Arsenic Trioxide Phebra Summary of Product Characteristics,
<https://www.medicines.org.uk/emc/product/10278/smpc>